USD10
DSGN Shares
About Design TherapeuticsDesign Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
USD10
DSGN Shares
About Design TherapeuticsDesign Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
Stats
TRADING WINDOW
Closed
OPENS AT
Jun 9 at 1:30 PM GMT+0
MARKET CAP
$653.3M
OPEN PRICE
Not enough data
LOW (1Y)
$3.33
HIGH (1Y)
$17.25
LOW (24H)
$10.11
HIGH (24H)
$11.00
VOLUME (24H)
$389.36K
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $10.70 | |
1 Week | $9.98 | |
1 Month | $15.07 | |
1 Year | $4.01 |
Past performance is not a reliable indicator of future results.
Discover more
Popular prediction markets
Popular price predictions
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.
